王憶卿 |
| Wang, Yi-Ching, Ph.D. |
| 職稱 |
| 講座教授(Chair professor) |
| 電話 |
| (06) 235-3535 ext 5502/5476 |
| 傳真 |
| (06) 274-9296 |
| ycw5798@mail.ncku.edu.tw |
| 『李國鼎科技與人文講座』榮譽學者訪談：王憶卿教授 | ||||||||||||||||||||||||||||
| 個人網站 |
||||||||||||||||||||||||||||
| 學經歷 |
||||||||||||||||||||||||||||
| 學歷：1993 密西根州立大學遺傳學 博士
經歷：1995 中山醫學大學分子毒理所 副教授 1999 臺灣師範大學生命科學系 教授 2006 成功大學醫學院藥理所 特聘教授 2015 成功大學醫學院藥理所 講座教授 |
||||||||||||||||||||||||||||
| 學科專長 | ||||||||||||||||||||||||||||
| 分子癌生物學，致癌蛋白轉錄調控，抑癌蛋白曩泡運輸，抗癌藥物及抗體研發。 | ||||||||||||||||||||||||||||
| 研究興趣 | ||||||||||||||||||||||||||||
|
王憶卿教授針對各種抑癌基因、致癌基因探討其變異性與肺癌形成的相關性；這些變異性研究包括基因突變、基因多形性、基因缺失、促進子過度甲基化、mRNA與蛋白質表達失常等分析。除了傳統的single-gene approach，王教授亦以genome-wide approach，針對癌細胞之基因體套數異常、基因體表現圖譜、基因體甲基化圖譜進行分析，希望能鑑定出更多許肺癌形成、早期偵測、預後監測的novel genes（新穎基因），目前研究NRF2致癌蛋白轉錄調控、Rab37囊泡運輸蛋白癌轉移抑癌機制，並建立細胞模式及動物模式研究抗癌藥物。王教授近三十年來於國際學術期刊發表了上百篇研究論文，並獲三次國科會/科技部傑出獎。希望在科學研究的過程中學習，並對台灣地區癌症的成因、預防、預後有所貢獻。 |
||||||||||||||||||||||||||||
| 實驗室人員 | ||||||||||||||||||||||||||||
| ‧ | 博士後研究員：謝智雄博士，郭琬婷 博士 | |||||||||||||||||||||||||||
| ‧ | 博士班學生：謝宏嘉、楊侑恩、蘇珮嘉、石馥瑄、劉薰 | |||||||||||||||||||||||||||
| ‧ | 碩士班學生：洪晨泰、林俞安、陳冠宇、何孟亭、張雄皓、許亞瑄、翁之浩 | |||||||||||||||||||||||||||
| ‧ | 研究助理：陳薏如 | |||||||||||||||||||||||||||
|
博士班畢業生： 曾若嘉博士（慈濟大學人類遺傳所副教授） 張哲維博士（財團法人生物技術開發中心研發經理） 湯硯安博士（成大基因體中心助理主任） 廖昇佑博士（美國UCLA博士後研究員） |
||||||||||||||||||||||||||||
| 碩士班畢業生： 蔡侑庭（美國 National Cancer Institute博士後研究員） 許貝君（台灣諾華臨床試驗分析專員） 魏子堂（台大藥理所副教授） 毛久珊（UCB - Medical Manager） 楊宗瀚（高醫大後醫系學生） 楊奕婕（沙鹿童綜合醫院於台北醫學大學助理研究員） 吳靜琪（成大醫院藥師） 陳湘婷（台南市七股區衛生所藥師） 蒲詩雯（衛福部食藥署助理審查員） 陳美瑜（台北榮總醫院藥師） 陳政宏（衛福部桃園醫院藥師） 陳其欣（台大公衛所專案助理教授） 黃鈺琳（Johnson & Johnson - 法規事務主管） 施詠馨（彰基醫院藥師） 李宗信（美商默沙東股份有限公司臨床試驗專員） 胡富涵（陽明大學微免所助教） 呂英鴻（高學醫學大學後醫學系） 林建瑜（高雄長庚醫研部生殖醫學實驗室研發專員）
陳奕潔（友霖生技醫藥臨床研究專員）
蘇靖欽（嘉義大林慈濟醫院藥師）
卓書慧 (宜蘭陽明大學附設醫院藥師）
吳莉婷（美國UCLA研發專員）
陳玉婷（佳生科技顧問公司研發專員）
林哲仲 (IQVIA艾昆緯公司臨床研究主任)
蔡宇柔 (北醫臨床試驗助理)
楊侑恩 (成大基醫所博士生）
黃士宣 (金萬林儀器- 產品專員)
楊佩姍 (成大藥理所研究助理）
謝宏嘉 (成大基醫所博士班）
胡孟璇 (松瑞製藥醫藥法規管理師)
余旻樺 (中國醫大跨領中心研究助理)
官彣徽 (高雄醫學大學研究助理)
吳思亭 (億康抗體公司研發專員)
劉易姍 (建台高中生物教師)
何沛萱(南光化學製藥臨床研究專員)
陳鏡宇
|
||||||||||||||||||||||||||||
| 代表性著作 | ||||||||||||||||||||||||||||
| . |
J . Jen, Y.-T. Chen, L.-T. Wu, C.-Y. Liu, Y.-C. Shieh, W.-W. Lai, Yi-Ching Wang*. 2018. Oncogenic zinc finger protein ZNF322A promotes stem cell-like properties in lung cancer through transcriptional suppression of c-Myc expression. Cell Death and Differentiation. DOI: 10.1038/s41418-018-0204-6
|
|||||||||||||||||||||||||||
| . |
H.-T. Tzeng, C.-C. Su, C.-P. Chang, W.-W. Lai, W.-C. Su, Yi-Ching Wang*. 2018. Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages towards tumor-suppressing phenotype. Int. J. Cancer. 143, 1753–1763. (cover article of Oct 1 2018 issue)
|
|||||||||||||||||||||||||||
| . |
S.-H. Cho, I.-Y. Kuo, P.-J. Lu, H.-T. Tzeng, W.-W. Lai, W.-C. Su, Yi-Ching Wang*. 2018. Rab37 mediates exocytosis of secreted frizzled-related protein 1 to inhibit Wnt signaling and thus suppress lung cancer stemness. Cell Death and Disease. 29;9(9):868.
|
|||||||||||||||||||||||||||
| . |
J. Jen, Y.-A. Tang, Y.-H. Lu, C.-C. Lin, H.-S. Hsu, W.-W. Lai, Yi-Ching Wang*. 2017. Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression. Mol Cancer 16(1):104.
|
|||||||||||||||||||||||||||
| . |
S.-Y. Liao, C.-W. Chiang, C.-H. Hsu, Y.-T. Chen, J. Jen, H.-F. Juan, W.-W. Lai, and Yi-Ching Wang*. 2017. CK1δ/GSK3b/FBXW7a axis promotes degradation of the ZNF322A oncoprotein to suppress lung cancer progression. Oncogene 36(41):5722-5733.
|
|||||||||||||||||||||||||||
| . |
J.-M., Shieh, Y.-A. Tang, F.-H. Hu, W.-J. Huang, Y.-J. Wang, T.-W. Wang P. Lin, Yi-Ching Wang*. 2017. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against non-small cell lung cancer. Int. J. Cancer 140(10):2375-2386.
|
|||||||||||||||||||||||||||
| . |
H.-T. Tzeng, C.-H. Tsai, Y.-T. Yen, H.-C. Cheng, Y.-C. Chen, S.-W. Pu, Y.-S. Wang, Y.-S. Shan, Y.-L. Tseng, W.-C. Su, W.-W. Lai, L.-W. Wu*, Yi-Ching Wang*. 2017. Dysregulation of Rab37-mediated cross-talk between cancer cells and endothelial cells via thrombospondin-1 promotes tumor neovasculature and metastasis. Clin. Cancer Res. 23(9):2335-2345. (highlighs of May 2017 issue)
|
|||||||||||||||||||||||||||
| . | Jayu Jen, Yi-Ching Wang*. 2016. Zinc finger proteins in cancer progression. J. Biomed. Sci. 23(1):53 (invited review) | |||||||||||||||||||||||||||
| . | H.-T. Tzeng, Yi-Ching Wang*. 2016. Rab-mediated vesicle trafficking in cancer. J. Biomed. Sci. 23(1):70 (invited review) | |||||||||||||||||||||||||||
| . | J. Jen, L.-L. Lin, H.-T. Chen, S.-Y. Liao, F.-Y. Lo, Y.-A. Tang, W.-C. Su, R. Salgia, C.-L. Hsu, H.-C. Huang, H.-F. Juan*, Yi-Ching Wang*. 2016. Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene 5;35(18):2357-69. | |||||||||||||||||||||||||||
| . | Y.-A. Tang, C.-H. Chen, H. S. Sun, C.-P. Cheng, V. S. Tseng, H.-S. Hsu, W.-C. Su, W.-W. Lai, Yi-Ching Wang*. 2015. Global Oct4 target gene analysis reveals novel downstream PTEN and TNC genes required for drug-resistance and metastasis in lung cancer. Nucleic Acids Res. 43(3):1593-608 | |||||||||||||||||||||||||||
| . | R.-C. Tseng, J.-M. Chang, J.-H. Chen, W.-R. Huang, Y.-A. Tang, I.-Y. Kuo, J.-J. Yan, W.-W. Lai, Yi-Ching Wang*. 2015. Deregulation of SLIT2-mediated Cdc42 activity is associated with esophageal squamous carcinoma cancer metastasis and poor prognosis. J. Thorac. Oncol. 10(1):189-198 | |||||||||||||||||||||||||||
| ‧ | Tsai CH, Cheng HC, Wang YS, Lin P, Jen J, Kuo IY, Chang YH, Liao PC, Chen RH, Yuan WC, Hsu HS, Yang MH, Hsu MT, Wu CY, Wang YC*. 2014. Small GTPase Rab37 targets tissue inhibitor of metalloproteinase 1 for exocytosis and thus suppresses tumor metastasis. Nat Commun 2014 Sep 3;5:4804 | |||||||||||||||||||||||||||
| . | Tseng RC, Chang JM, Chen JH, Huang WR, Tang YA, Kuo IY, Yan JJ, Lai WW*, Wang YC*. 2014. Deregulation of SLIT2-mediated Cdc42 activity is associated with esophageal squamous carcinoma cancer metastasis and poor prognosis. J. Thorac. Oncol. doi: 10.1097/JTO.00369 | |||||||||||||||||||||||||||
| ‧ | Lin RK, Wang YC*. 2014. Dysregulated transcriptional and post-translational control of DNA methyltrasferases in cancer. Cell Biosci 2014 4: 46 (invited review) | |||||||||||||||||||||||||||
| ‧ |
Cheng CP, Kuo IY, Alakus H, Frazer KA, Harismendy O, Wang YC*, Tseng VS*. 2014. Network-based analysis identifies epigenetic biomarkers of esophageal squamous cell carcinoma progression. Bioinformatics 2014 Jul 10. pii: btu433. |
|||||||||||||||||||||||||||
| . | Yang YC, Tang YA, Shieh JM, Lin RK, Hsu HS, Wang YC*. 2014. DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repression and MDM2 overexpression in lung cancer. J. Thorac. Oncol. 9(9):1305-15. | |||||||||||||||||||||||||||
| ‧ | Tseng RC, Huang WR, Lin SF, Wu PC, Hsu HS, Wang YC*. 2014. HBP1 promoter methylation augments the oncogenic β-catenin to correlate with prognosis in NSCLC. J. Cell Mol. Med. 18(9):1752-61. | |||||||||||||||||||||||||||
| ‧ |
Huang WJ, Tang YA, Chen MY, Wang YJ, Hu FH, Wang TW, Chao SW, Chiu HW, Yeh YL, Chang HY, Juan HF, Lin P, Wang YC*. 2014. A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies. Cancer Lett 28;346:84-93 (featured article). |
|||||||||||||||||||||||||||
| ‧ | Kuo IY, Wu CC, Chang JM, Huang YL, Lin CH, Yan JJ, Sheu BS, Lu PJ, Chang WL, Lai WW*, Wang YC*. 2014. Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression. Int J Cancer 135: 563-573 (cover article). | |||||||||||||||||||||||||||
| ‧ | Chang HY, Huang HC, Huang TC, Yang PC*, Wang YC*, Juan HF*. 2012. Ectopic ATP synthase blockade suppresses lung adenocarcinoma growth by activating the unfolded protein response. Cancer Res, 72:4696-4706. | |||||||||||||||||||||||||||
| . | Tang YA, Lin RK, Tsai YT, Hsu HS, Yang YC, Chen CY, Wang YC*. 2012. MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer. Clin. Cancer Res. 18:4325-4333. | |||||||||||||||||||||||||||
| . | Lo FY, Tan YH, Cheng HC, Salgia R, Wang YC*. 2011. An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer 117:5344-50 (highlighted article). | |||||||||||||||||||||||||||
| ‧ | Chen JY, Tang YA, Huang SM, Juan HF, Wu LW, Sun YC, Wang SC, Wu KW, Balraj G, Chang TT, Li WS*, Cheng HC*, Wang YC*. 2011. A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer Angiogenesis and Metastasis Pathways. Cancer Res. 71:473-483. | |||||||||||||||||||||||||||
| . | Lin RK, Wu CY, Chang JW, Juan LJ, Hsu HS, Chen CY, Lu YY, Tang YA, Yang YC, Yang PC, Wang YC*. 2010. Dysregulation of p53/Sp1 control leads to DNA methyltransferase 1 overexpression in lung cancer. Cancer Res. 70:5807-5817. | |||||||||||||||||||||||||||
| . | Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, Tang YA, Lee CF, Wang YC*. 2010. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J. Clin. Invest., 120:521–532 (cover article). | |||||||||||||||||||||||||||
| ‧ | Tseng RC, Lee SH, Hsu HS, Chen BH, Tsai WC, Tzao C*, Wang YC*. 2010. SLIT2 attenuation during lung cancer progression deregulates beta-catenin and E-cadherin and associates with poor prognosis. Cancer Res., 70: 543-551. | |||||||||||||||||||||||||||
| 獎助 | ||||||||||||||||||||||||||||
| . |
傑出人才基金會 [傑出人才講座] 2022-2024 [The Foundation for the Advancement of Outstanding Scholarship Award] |
|||||||||||||||||||||||||||
| . |
李國鼎科技人文講座 [榮譽學者獎] 2018 [K. T. Li Honorary Scholar Award] |
|||||||||||||||||||||||||||
| . |
第27屆王民寧獎 [醫藥科技傑出貢獻獎] 2017 [Dr. Wang Min-Ning Memory Foundation for Excellent Basic Medical Research award] |
|||||||||||||||||||||||||||
| . |
科技部特約研究 2017-2023 [Merit MOST Research Fellow Award] |
|||||||||||||||||||||||||||
| ‧ |
三次科技部/ 國科會傑出獎 2004-2007, 2010-2013,2014-2017 [E xcellent Research award of National Science Council, Taiwan. (2004-2007 , 2010-2013,2014-2017 )] |
|||||||||||||||||||||||||||
| ‧ | 成功大學講座教授 2014-2017 [Chair professor of National Cheng Kung University (2014-2017)] | |||||||||||||||||||||||||||
| ‧ |
成功大學特聘教授 1997-至今 [Distinguished professor of National Cheng Kung University (1997-Now)] |
|||||||||||||||||||||||||||
| ‧ | 董大成癌症基礎研究傑出獎 2013 | |||||||||||||||||||||||||||
| ‧ |
成大醫學院最佳論文獎 2010 [Outstanding publication award of National Cheng Kung University 2010] |
|||||||||||||||||||||||||||
| ‧ |
成杏基金會優秀論文獎 2008-至今Excellent paper award of Cheng Hsin Medical Society 2008- Now] |
|||||||||||||||||||||||||||
| ‧ | 藥理學會傑出研究獎 [Excellent Research award in Pharmacology Society, Taiwan. (2008)] | |||||||||||||||||||||||||||
| ‧ | 文化大學傑出校友 [Distinguished alumnus of Chinese Culture University, (2007)] | |||||||||||||||||||||||||||
| 目前之研究計畫 | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||